Back to News
Market Impact: 0.25
Acrivon Therapeutics, Inc. Acquires Oral JAK1 Inhibitor ACR-525 and PKCθ Preclinical Program from Aqilion AB
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
On November 6, 2026, Acrivon Therapeutics announced it acquired Aqilion AB’s programs for discovery, research and development of oral JAK1 inhibitors under an asset purchase agreement. The article excerpt provides no purchase price, development milestones or other deal terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
ACRV0.45
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO